[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338848-105":59,"doc-detail-338848-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-pancancer-analysis-of-the-clinical-and-genomic-characteristics-of-multiple-primary-cancers","A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers","","A pancancer investigation evaluates clinical and genomic features of multiple primary cancer (MPC) using 11,000 TCGA patients (1993–2013), separating individuals with and without prior malignant history. MPC incidence increases to 8.5–13.1% since 2000, with higher risk in elderly patients, males, early-stage disease, and certain racial groups. Non-MPC patients show longer overall and disease-free survival. SEER-based assessment in one center identifies MPC across 380 of 801 events, with secondary peaks 1–5 years and again at 10–15 years. Elevated tumor mutational burden in MPC suggests an immunotherapy-relevant biomarker.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-pancancer-analysis-of-the-clinical-and-genomic-characteristics-of-multiple-primary-cancers/338848/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-pancancer-analysis-of-the-clinical-and-genomic-characteristics-of-multiple-primary-cancers/338848.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were MPC patients identified in this study?","Question",{"text":113,"@type":114},"MPC status was determined using TCGA history variables, classifying patients with prior malignancy history as the MPC group and others as the non-MPC group.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What survival differences were observed between MPC and non-MPC patients?",{"text":118,"@type":114},"Non-MPC patients had significantly longer overall survival and disease-free survival compared with MPC patients.",{"name":120,"@type":111,"acceptedAnswer":121},"What genomic factor may be clinically important for MPC?",{"text":122,"@type":114},"Skin cutaneous melanoma and the MPC group can show higher tumor mutational burden, and high TMB was linked to improved survival, suggesting potential relevance for immunotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338848,1790212042,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA pancancer analysis of the clinical and genomic characteristics of multiple primary cancers  \nBaiwen Zhang1,2, Lina He1,2, Cong Zhou1, Xiaojiao Cheng1, Qingli Li1, Yao Tang1, Fuli Li1, Tinglei Huang1 & Shuiping Tu1*  \nMultiple primary cancer (MPC) denotes individuals with two or more malignant tumors occurring simultaneously or successively. Herein, a total of 11,000 pancancer patients inTCGA database (1993– 2013) were divided into MPC or non-MPC groups based on their history of other malignant tumors. The incidence of MPC has risen to 8.5–13.1% since 2000. Elderly individuals, males, early-stage cancer patients, and African Americans and Caucasians are identified as independent risk factors (p \u003C 0.0001) . Non-MPC patients exhibit significantly longer overall survival (OS) and disease-free survival (DFS)(p = 0.0038 and p = 0.0014). Age (p \u003C 0.001) and tumor staging at initial diagnosis (p \u003C 0.001) contribute to this difference. In our center, MPC was identified in 380 out of 801 tumor events based on SEER criteria. The peak occurrence of secondary primary was about 1–5 years after the first primary tumor, with a second small peak around 10–15 years. Multiple tumors commonly occur in the same organ (e.g., breast and lung), constituting 12.6%. Certain cancer types, notably skin cutaneous melanoma (SKCM), exhibit significantly higher tumor mutational burden (TMB) in the MPC group (17.31 vs. 6.55 mutations/MB, p \u003C 0.001), with high TMB associated with improved survival (p \u003C 0.001) . High TMB in MPC may serve as a predictor for potential immunotherapy application.  \nMultiple primary cancer (MPC) refers to the presence of two or more malignant tumors in the same or different organs or tissues simultaneously or successively. These tumors, pathologically and histologically considered cancers from different primary sites, are mainly distinguishing them from tumor recurrence and metastasis1. MPC can be classified into synchronous multiple primary cancer (SMPC) or metachronous multiple primary cancer (MMPC) based on the time interval between the second tumor and the primary tumor. The diagnosis of MPC has evolved, and two main criteria, established by the Surveillance Epidemiology and End Results (SEER) Program and the International Association of Cancer Registries and International Agency for Research on Cancer (IACR/IARC) organization, are commonly used in studies2. Differences in these criteria include the understanding of the primary site and the definition of SMPC and MMPC2. In this study, we utilized SEER asthe main diagnostic criteria.  \nAt present, the incidence of multiple primary tumors in different studies ranges from 1.63 to 10.9%1,3–6. The risk of developing multiple primary tumors increases with a longer follow-up duration, reaching 4.3%, 7.7%, and 12.4% over an average follow-up period of 5, 10, and 20 years, respectively7. This heightened risk is primarily associated with age, as evidenced by a significant increase in incidence from 1% for a 30-year-old person to 18% for a 70-year-old person8. Individual with a history of cancer face a 14% increased risk of getting another primary tumor compared to the general population9. The risk of tumor recurrence varies depending on the typeof first primary tumor, with a 1% recurrence risk for primary liver cancer and 16% for primary bladder cancer10. Factors influencing the incidence of multiple primary tumors include the location of the first primary tumor, age at initial diagnosis, environmental exposure factors, genetic factors, and previous treatment1.  \nHerein, we analyzed clinical and genomic data from large-scale sequencing data in The Cancer Genome Atlas (TCGA) database to enhance understanding and identify effective strategies for preventing and managing multiple primary tumors, ultimately improving prognosis and therapeutic methods.  \n1Department of Oncology, State Key Laboratory of Systems Me","cbCaitB51EEq53Lu","https://ap.wps.com/l/cbCaitB51EEq53Lu","pdf",7311849,"English","# Materials and methods\n## Data acquisition\n## Data processing and analysis\n## Cases enrolled in our center","[{\"question\":\"How were MPC patients identified in this study?\",\"answer\":\"MPC status was determined using TCGA history variables, classifying patients with prior malignancy history as the MPC group and others as the non-MPC group.\"},{\"question\":\"What survival differences were observed between MPC and non-MPC patients?\",\"answer\":\"Non-MPC patients had significantly longer overall survival and disease-free survival compared with MPC patients.\"},{\"question\":\"What genomic factor may be clinically important for MPC?\",\"answer\":\"Skin cutaneous melanoma and the MPC group can show higher tumor mutational burden, and high TMB was linked to improved survival, suggesting potential relevance for immunotherapy.\"}]","A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers | PDF",1790026135,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9612d64b4da3547058db4b7d43d41c98.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab58846eb3e2fa2befd4588aa965b75c.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b50a713056ff78fd593f19c29189d81f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/650e10c880988e1695bf9abf2ffbada0.webp",980,1287]